Use of SGLT2i after kidney transplantation, first experiences

AUTHOR(S) / АУТОР(И): Neven Vavić , Jelena Tadić, Katarina Obrenčević

Download Full Pdf   

DOI: 10.46793/KARNEF25.165V

ABSTRACT / САЖЕТАК:

Recent large randomized trials have demonstrated the benefit of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in improving renal and CV outcomes in patients (pc) with chronic kidney disease. According to the new KDIGO guidelines, SGLT2i are the first choice of treatment for diabetics with chronic kidney disease (CKD), but also for other pc with CKD and pc with heart failure with or without diabetes (DM). However, there is insufficient data on the efficacy and safety of SGLT2i administration in pc after renal transplantation (KTP) with or without DM, since, due to safety concerns, these PC were not included in randomized studies that resulted in the clinical use of this group of drugs in CKD PC. Currently, there are limited literature data, mostly related to the short-term efficacy and safety results of SGLT2i administration in KTP. For now, there is a lack of data related to the long-term outcomes of kidney graft survival and the frequency of CV complications in these PCs. In the paper, we analyzed 15 PCs who underwent kidney transplantation (KT) in our institution and who were administered SGLT2i. The drug was administered at an interval of 1 month to 5 years, and was introduced in a period of 8 months to 10 years after CT. The reasons for the administration of the drug were chronic graft dysfunction with or without proteinuria. The frequency of side effects was not high. We draw attention to the necessity of greater clinical caution when applying SGLT2i in KTP in conditions of general condition disturbances, possible dehydration and/or hypotension, such as various febrile conditions, vomiting and diarrheal syndrome, where the possibility of acute graft dysfunction and symptoms of drug intolerance can easily and quickly occur.

KEYWORDS / КЉУЧНЕ РЕЧИ:

SGLT2i, kidney transplantation

REFERENCES / ЛИТЕРАТУРА:

• Baigent, ColinAnker, Stefan D. et al Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials The Lancet, Volume 400, Issue 10365, 1788 – 1801.
• van der Aart-van der Beek A.B., de Boer R.A., Heerspink H.J.L. Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol. 2022;18:294–306.
• Rossing, Peter et al.Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence Kidney International, Volume 102, Issue 5, 990 – 999.
• Ujjawal A, Schreiber B, Verma A. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence? Ther Adv Endocrinol Metab. (2022) 13:20420188221090001
• Mahling M, Schork A, Nadalin S, Fritsche A, Heyne N, Guthoff M. Sodium glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus. Kidney Blood Press Res. (2019) 44:984–92.
• Tonelli, N. Wiebe, G. Knoll, A. Bello, S. Browne, D. Jadhav, S. Klarenbach, J. Gill Systematic Review: Kidney Transplantation Compared With Dialysis in Clinically Relevant Outcomes,American Journal of Transplantation,Volume 11, Issue 10,2011.
• Song CC, Brown A, Winstead R, Yakubu I, Demehin M, Kumar D, et al. Early initiation of sodium-glucose linked transporter inhibitors (SGLT-2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients. Endocrinol Diabetes Metab. (2021) 4:e00185.
• Chewcharat A, Prasitlumkum N, Thongprayoon C, Bathini T, Medaura J, Vallabhajosyula S, et al. Efficacy and safety of SGLT-2 inhibitors for treatment of diabetes mellitus among kidney transplant patients: A systematic review and meta analysis. Med Sci (Basel). (2020) 8:47.